Leadership at Avadel Pharmaceuticals
Our management team is key to the success of our company. We are lead by a diverse team of experts in their respective fields, each of whom help to ensure the success of our business and ultimately the well-being of patients.
Gregory J. Divis, CEO
Gregory J. Divis was named Chief Executive Officer in June of 2019, after having served as Chief Operating Officer (named in March 2018) and Executive Vice President and Chief Commercial Officer (named in January 2017). Prior to joining Avadel, he served as an Executive in Residence at Linden Capital Partners, a healthcare-focused private equity firm. With over 25 years of experience in the pharmaceutical industry, Mr. Divis served as President and Chief Executive Officer of Lumara Health, a specialty branded pharmaceutical company focused on women’s health. Prior to Lumara, Mr. Divis held general management, sales, marketing and business development roles at Schering Plough and Sanofi-Aventis.
Jordan Dubow, M.D., Chief Medical Officer
Jordan Dubow was appointed Chief Medical Officer in April 2019. Prior to joining Avadel, Dr. Dubow was employed from November 2018 until April 2019 by Esteve Pharmaceuticals, S.A., a pharmaceutical company headquartered in Barcelona, Spain, where he served as Vice President, CNS Therapeutic Strategy and was responsible for evaluating in-licensing candidates and provided regulatory and clinical support for Esteve’s entire development pipeline. From July 2016 until October 2018, Dr. Dubow was employed by Clintrex, a strategic advisory firm to the pharmaceutical industry, where he served as Vice President of Clinical & Medical Affairs, providing clinical, regulatory and business development support in the field of neurological diseases. From July 2015 until June 2016, Dr. Dubow was employed by Marathon Pharmaceuticals, a biopharmaceutical company focused on developing and commercializing therapies for neurological disorders, and served as Chief Medical Officer. Prior to Marathon Pharmaceuticals, Dr. Dubow was Vice President, Medical Affairs at Cynapsus Therapeutics, and Medical Director, Neuroscience Clinical Development at AbbVie. Dr. Dubow has both depth and breadth of experience in managing clinical development, medical affairs, business development and regulatory affairs, including multiple successful NDA submissions to the U.S. Food and Drug Administration, across a wide range of neurological diseases including sleep disorders such as narcolepsy. He is a board-certified neurologist who received his M.D. from the Northwestern University Feinberg School of Medicine. He has numerous peer-reviewed publications in neurological disorders and has served as a reviewer for various neurological journals.
Thomas S. McHugh, Chief Financial Officer
Thomas McHugh was appointed Chief Financial Officer in December 2019. Prior to joining Avadel, Mr. McHugh served as Senior Vice President of Finance of Ironshore Pharmaceuticals Inc. where he built and led the U.S. Finance, Accounting and Treasury functions and supported Ironshore’s new product launch. Prior to his time at Ironshore, McHugh was the Chief Financial Officer and Treasurer at Lumara Health, a specialty pharmaceutical company that focused on maternal fetal medicine and obstetrics/gynecology. While at Lumara he supported a number of key strategic initiatives, including a new product launch, a restructuring and a sale of the company. Prior to joining Lumara, Tom was a Managing Director and Global Controller at BearingPoint, a global consultancy. Before joining BearingPoint, he was the Chief Financial Officer at Huttig Building Products, Inc. (NASDAQ: HBP). Tom began his career in public accounting at PricewaterhouseCoopers. Tom earned his bachelor’s degree in finance from Bentley University and a master’s degree in accounting from Northeastern University.
Dr. Jason M. Vaughn, SVP, Technical Operations
Dr. Jason Vaughn was appointed Senior Vice President of Technical Operations in December 2019. Prior to joining Avadel, Dr. Vaugh was Principal at Wyatt Pharma Consulting, LLC where he led several development programs for client companies, including Avadel. Prior to this, he was Senior Director and Vice President, Process Technology Development for the North American region of Patheon Pharmaceuticals, a ThermoFisher Scientific company. In this role, he was responsible for assisting client companies in the development, scale-up and commercialization of their products. Additionally, Dr. Vaughn led teams to solve challenging technical problems involving formulation and manufacturing of oral pharmaceuticals and controlled release technologies. He also served as Vice President, Pharmaceutical Development for Banner Life Sciences, a specialty pharmaceutical company focused on developing products using the 505(b)2 pathway. He led technical teams developing a number of oral, modified release products for IND enabled clinical studies, registration, scale-up, NDA regulatory submission and commercialization readiness for products, including Bafiertam™, which has received tentative FDA approval. Prior to Joining Banner, Jason served as Director, Formulation Development for Patheon Pharmaceuticals in Cincinnati, OH, leading teams focused on development, scale-up, registration and commercialization of oral modified release dosage. He received a B.S. in Pharmacy and a Ph.D. in Pharmaceutics from the University of Texas at Austin.